Drug Profile

CLD 401

Alternative Names: CLD-401

Latest Information Update: 08 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Calidi Biotherapeutics
Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
Mechanism of Action CD55 antigen stimulants; Cell death stimulants; Immunologic cytotoxicity; Interleukin 15 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

30 Oct 2025 Calidi Biotherapeutics plans to file an Investigational New Drug (IND) application by the end of 2026.
03 Jun 2025 Early research in Solid tumours in USA (IV), Prior to June 2025
02 Jun 2025 CLD 401 is available for licensing as of 02 Jun 2025. https://www.calidibio.com/pipeline/

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com